Brokers Set Expectations for Celldex Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) – Research analysts at SVB Leerink issued their FY2027 EPS estimates for Celldex Therapeutics in a research note issued on Thursday, January 19th. SVB Leerink analyst T. Smith anticipates that the biopharmaceutical company will post earnings of ($2.78) per share for the year. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.43) per share.

Celldex Therapeutics (NASDAQ:CLDX – Get Rating) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, meeting the consensus estimate of ($0.57). Celldex Therapeutics had a negative net margin of 9,840.85% and a negative return on equity of 25.47%. The business had revenue of $0.41 million during the quarter, compared to the consensus estimate of $0.25 million.

CLDX has been the subject of several other reports. Guggenheim lowered their price target on shares of Celldex Therapeutics from $68.00 to $63.00 and set a “buy” rating for the company in a report on Friday, November 11th. StockNews.com upgraded shares of Celldex Therapeutics to a “sell” rating in a report on Tuesday, December 27th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $66.67.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $46.61 on Friday. The firm has a 50 day simple moving average of $40.77 and a two-hundred day simple moving average of $34.58. The company has a market cap of $2.20 billion, a P/E ratio of -20.62 and a beta of 2.21. Celldex Therapeutics has a one year low of $19.85 and a one year high of $48.40.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its holdings in Celldex Therapeutics by 109.0% in the third quarter. Nisa Investment Advisors LLC now owns 1,024 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 534 shares during the period. Point72 Hong Kong Ltd increased its holdings in Celldex Therapeutics by 57.9% in the first quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 511 shares during the period. Great West Life Assurance Co. Can acquired a new stake in Celldex Therapeutics in the third quarter valued at $58,000. Atlas Capital Advisors LLC acquired a new stake in Celldex Therapeutics in the third quarter valued at $76,000. Finally, Virtus ETF Advisers LLC increased its holdings in Celldex Therapeutics by 16.6% in the second quarter. Virtus ETF Advisers LLC now owns 4,816 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 685 shares during the period.

Celldex Therapeutics Company Profile

(Get Rating)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.